Trial Profile

A First-In-Human, Phase 1, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GFB-887, a TRPC5 Channel Inhibitor, in Healthy Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 04 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GFB 887 (Primary)
Indications Diabetic nephropathies; Focal segmental glomerulosclerosis; Polycystic kidney disease
Focus Adverse reactions; First in man; Pharmacokinetics
Sponsors Goldfinch Bio

Most Recent Events

27 Jul 2021 According to a Goldfinch Biomedia release, data from this trial will be presented at the 13th International Podocyte Conference 2021, taking place online and at the University of Manchester.
22 Oct 2020 Results published in the Media Release
22 Oct 2020 According to a Goldfinch Bio media release, data from this study were presented at the American Society of Nephrology (ASN) Kidney Week 2020 Annual Meeting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com